Oxford BioTherapeutics to announce new fully integrated ADC Engine at World ADC Conference 2023

• Engine will combine OBT’s internationally recognised target discovery and ADC development capabilities
• OBT will also present a case study and two abstracts focussing on its recent novel target discovery and high-impact partnership outputs leveraging its proprietary proteomic database OGAP® at the 13th Annual World ADC Conference 

Oxford, UK and San Jose, Calif., 9 March 2023 - Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced it will reveal its new fully integrated ADC engine, combining its internationally recognised target discovery and ADC development capabilities, at the 13th Annual World ADC Conference being held in London, UK, from 13 to 16 March 2023. The company will also present an ADC case study and two abstracts, focusing on its recent novel target discovery and high impact partnership outputs leveraging its proprietary proteomic database OGAP®. 

“I am delighted to announce OBT’s novel, fully integrated ADC engine, which brings together our internal capabilities in target discovery and drug design and development,” said Christian Rohlff, CEO, Oxford BioTherapeutics. “This is an important step in OBT’s continued growth, and in strengthening the sustainability of our internal pipeline, while simultaneously furthering our mission to discover and develop novel therapeutics to meet unmet needs in cancer."

“We are very pleased to have a significant company presence at this year’s World ADC Conference and to present abstracts highlighting our proprietary OGAP® platform and our ADC collaboration with ImmunoGen. The conference is always an outstanding place to learn about advancements in cutting edge research in the field, and we are very much looking forward to meeting peers in the industry and discussing the latest science that could have significant positive impacts for patients."

The case study, presented by CEO Christian Rohlff, will highlight the potential of ADCs to reengage the immune system to make more patients, including those previously resistant, eligible for checkpoint inhibitor (CPI) therapy. 

OBT’s lead candidate, OBT076, has been shown to deliver this immune priming, based on Phase I data presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, where near complete responses were observed in two chemo-refractory advanced cancer patients with low PDL1 expression after a dosing regimen of 2-5 cycles of OBT076 followed by 1-2 cycles of a CPI.

The two World ADC Conference abstracts describe the latest high-impact outputs from OBT’s proprietary proteomic database OGAP® and its ongoing collaboration with ImmunoGen to develop multiple, first-in-class ADCs. OGAP® was used to discover and construct OBT’s lead candidate, OBT076, which is in Phase 1b clinical development in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed.